




The relative strengths and weaknesses of Crescent Biopharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Crescent Biopharma INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 103% points. The greatest weakness of Crescent Biopharma INC is the variable Research and Development, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 377%, being 123% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	56,115
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,461
Liabilities, Non-Current	0
Other Assets	697
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	18
Other Revenues	15,027
Property and Equipment	452
Research and Development	19,571
Selling, General and Administrative Expense	6,596

Output Variable	Value in 1000 USD
Assets	57,264
Liabilities	6,461
Expenses	26,167
Revenues	15,027
Stockholders Equity	50,803
Net Income	-11,122
Comprehensive Net Income	-11,122
BaseVar	52,468
ECR before Limited Liability	313%
Economic Capital Ratio	377%